Jazz reports surprise PhIII flop for cannabinoid drug from $7.2B GW buyout
In a surprise setback, Jazz Pharmaceuticals says a cannabinoid it acquired from GW has failed a key Phase III trial.
The RELEASE MSS1 trial, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
